Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs is a monthly peer-reviewed journal published by Taylor & Francis, covering pharmacology and drug development. Founded in 1992, it provides authoritative evaluations of investigational drugs in all therapeutic areas, with a 2025 impact factor of 4.3, indexed in SCIE.《研究性药物专家意见》（Expert Opinion on Investigational Drugs, 简称 EOID）是由 Taylor & Francis 出版的月刊同行评审期刊，涵盖药理学与药物开发。该刊创刊于 1992 年，提供所有治疗领域研究性药物的权威评价，2025 年影响因子为 4.3，被 SCIE 收录。
Scope
The journal's stated aim is to provide systematic, expert opinion on investigational drugs in all therapeutic areas, with its official scope covering:刊物官方宗旨为提供所有治疗领域研究性药物的系统性专家意见，官方声明的征稿范围包括：
- Drug discovery and development: original expert evaluations on compounds in preclinical and clinical development across all therapeutic areas.药物发现与开发： 关于所有治疗领域临床前与临床开发阶段化合物的原创专家评价。
- Clinical trials: expert reviews on the design, conduct, and outcomes of clinical trials for investigational drugs.临床试验： 关于研究性药物临床试验设计、实施与结局的专家综述。
- Pharmacology and mechanism of action: studies on the pharmacological properties, mechanisms of action, and pharmacokinetic profiles of investigational drugs.药理学与作用机制： 关于研究性药物药理特性、作用机制与药代动力学特征的研究。
- Therapeutic areas: expert evaluations of investigational drugs across therapeutic areas including oncology, cardiovascular, infectious disease, central nervous system, and inflammation.治疗领域： 关于肿瘤、心血管、传染病、中枢神经系统与炎症等治疗领域研究性药物的专家评价。
- Article types: the journal publishes expert opinion reviews, drug evaluations, and editorial perspectives on investigational drugs and their clinical potential.栏目设置： 该刊发表关于研究性药物及其临床潜力的专家意见综述、药物评价与编辑观点。
History
- Founding: the journal was established in 1992 as part of the Expert Opinion series of journals focusing on the drug development pipeline.创刊： 该刊于 1992 年创刊，是聚焦药物开发管线的专家意见系列期刊之一。
- Taylor & Francis publication: EOID is published by Taylor & Francis under the Expert Opinion series, ensuring high editorial standards and expert contributions.Taylor & Francis 出版： EOID 由 Taylor & Francis 出版，隶属专家意见系列，确保高编辑标准与专家贡献。
- Drug development focus: throughout its history, the journal has specialized in evaluating investigational drugs, providing critical insights for drug developers and clinicians.药物开发聚焦： 在其发展历程中，该刊专注于评价研究性药物，为药物开发者与临床医生提供关键洞察。
- Publication frequency: the journal publishes monthly, providing regular updates on investigational drugs across all therapeutic areas.出版频率： 该刊每月出版，定期更新所有治疗领域的研究性药物进展。
Editors
The journal is led by an editor-in-chief supported by associate editors and an editorial board:该刊由主编领导，副主编与编委会协助工作：
- Editor-in-chief: Naim Alkhouri, MD of Summit Clinical Research, San Antonio, Texas, and the Clinical Research Institute of Ohio, Westlake, Ohio, United States, serves as the editor-in-chief.主编： 美国得克萨斯州圣安东尼奥 Summit 临床研究中心与俄亥俄州西湖俄亥俄临床研究所的纳伊姆·阿尔胡里（Naim Alkhouri, MD）担任主编。
- Associate editors: the editor-in-chief is supported by associate editors with expertise across major therapeutic areas and drug development stages.副主编： 主编由具有主要治疗领域与药物开发阶段专长的副主编协助。
- Editorial board: the journal has a large international editorial board comprising clinical pharmacologists and drug development experts from leading institutions and companies worldwide.编委会： 该刊拥有大型国际编委会，成员为来自全球顶尖机构与企业的临床药理学家与药物开发专家。
- Open access option: authors can choose to publish open access in this journal, making their articles freely available to readers upon publication in exchange for an article processing charge.开放获取选项： 作者可选择在该刊发表开放获取文章，使论文发表后即向读者免费开放，并支付文章处理费。